×
0 0 0 0 0.00673211781206177 0.00673211781206177 0.00673211781206177 0.00673211781206177
Stockreport

FDA approves first drug for inherited breast cancer [CBS News]

ASTRAZENECA (AZN)  More Company Research Source: CBS News
Last astrazeneca earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF FDA approves first drug to treat inherited breast cancer Lynparza, the first FDA-approved drug aimed at women with advanced breast cancer caused by an inherited flawed gene. U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene. The Food and Drug Administration on Friday approved AstraZeneca PLC's Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy. The drug has been on the market since 2014 for ovarian cancer , and is the first in a new class of medicines called PARP inhibitors to be approved for breast cancer. PARP inhibitors prevent cancer cells from fixing problems in their DNA. Lynparza will cost $13,886 per month without insurance, according to AstraZeneca. The company is offering patients financial assistance. "While there is currently no cure for metastatic breast cancer, today's approval offers a new, targeted option that may help to delay disease progression for th [Read more]

IMPACT SNAPSHOT EVENT TIME: AZN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AZN alerts
from News Quantified